- Home
- CNTB vs ATRA Comparison
CNTB vs ATRA Comparison
Compare CNTB & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- ATRA
- Stock Information
- Founded
- CNTB 2012
- ATRA 2012
- Country
- CNTB United States
- ATRA United States
- Employees
- CNTB N/A
- ATRA N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTB Health Care
- ATRA Health Care
- Exchange
- CNTB Nasdaq
- ATRA Nasdaq
- Market Cap
- CNTB 54.4M
- ATRA 51.1M
- IPO Year
- CNTB 2021
- ATRA 2014
- Fundamental
- Price
- CNTB $2.00
- ATRA $11.55
- Analyst Decision
- CNTB Strong Buy
- ATRA Strong Buy
- Analyst Count
- CNTB 2
- ATRA 4
- Target Price
- CNTB $7.50
- ATRA $20.00
- AVG Volume (30 Days)
- CNTB 280.7K
- ATRA 68.0K
- Earning Date
- CNTB 09-04-2025
- ATRA 08-11-2025
- Dividend Yield
- CNTB N/A
- ATRA N/A
- EPS Growth
- CNTB N/A
- ATRA N/A
- EPS
- CNTB N/A
- ATRA N/A
- Revenue
- CNTB $26,033,000.00
- ATRA $199,732,000.00
- Revenue This Year
- CNTB N/A
- ATRA N/A
- Revenue Next Year
- CNTB N/A
- ATRA N/A
- P/E Ratio
- CNTB N/A
- ATRA N/A
- Revenue Growth
- CNTB N/A
- ATRA 475.53
- 52 Week Low
- CNTB $0.51
- ATRA $5.01
- 52 Week High
- CNTB $2.86
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- CNTB 59.15
- ATRA 62.28
- Support Level
- CNTB $1.70
- ATRA $10.68
- Resistance Level
- CNTB $2.45
- ATRA $12.85
- Average True Range (ATR)
- CNTB 0.36
- ATRA 1.11
- MACD
- CNTB -0.02
- ATRA 0.02
- Stochastic Oscillator
- CNTB 42.51
- ATRA 61.26
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).